[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634722":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":28,"responsibleParty":63,"collaborators":18,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":18,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":18,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":31,"whyStopped":18,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Pfizer","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"RSVpreF","EXPERIMENTAL","RSV Vaccine",[13],"Biological: RSVpreF",[15],{"type":16,"name":9,"description":11,"armGroupLabels":17,"otherNames":18},"BIOLOGICAL",[9],null,[20],{"name":21,"affiliation":5,"role":22},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[24],{"name":21,"role":25,"phone":26,"phoneExt":18,"email":27},"CONTACT","1-800-718-1021","ClinicalTrials.gov_Inquiries@pfizer.com",[29,43,48,51,54],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":18},"Tsuchiura Beryl Clinic","RECRUITING","Tsuchiura","Ibaraki","300-0062","Japan","JP",{"type":38,"coordinates":39},"Point",[40,41],140.21047,36.09047,{"lat":41,"lon":40},{"facility":44,"status":31,"city":45,"state":46,"zip":47,"country":35,"countryCode":36,"cosmosGeoPoint":18,"geoPoint":18,"contacts":18},"Nihonbashi Sakura Clinic","Chuo-ku","Tokyo","103-0025",{"facility":49,"status":31,"city":45,"state":46,"zip":50,"country":35,"countryCode":36,"cosmosGeoPoint":18,"geoPoint":18,"contacts":18},"Tokyo-Eki Center-building Clinic","103-0027",{"facility":52,"status":31,"city":45,"state":46,"zip":53,"country":35,"countryCode":36,"cosmosGeoPoint":18,"geoPoint":18,"contacts":18},"Fukuwa Clinic","104-0031",{"facility":55,"status":31,"city":56,"state":18,"zip":57,"country":35,"countryCode":36,"cosmosGeoPoint":58,"geoPoint":62,"contacts":18},"Tenjin Sogo Clinic","Fukuoka","810-0021",{"type":38,"coordinates":59},[60,61],130.41667,33.6,{"lat":61,"lon":60},{"type":64,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100634722","phase-3-a-study-to-learn-safety-and-immune-response-to-study-vaccine--rsvpref-in-adults-at-high-risk-of-severe-rsv-disease-100634722",false,"NCT07543380","A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.","A PHASE 3, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS CONSIDERED AT HIGH RISK OF SEVERE RSV DISEASE IN JAPAN","Key Inclusion Criteria:\n\n• Underlying health condition(s) that can put the participant at an increased risk of severe RSV\u002Fcomplications including chronic lung , heart, kidney, liver, nervous system, blood, or metabolic diseases\n\nKey Exclusion Criteria:\n\n* Received any kind of RSV vaccine before participating in this study\n* Determined as not eligible by the investigator based on the participant's past and present health condition(s), medication(s) and treatment(s)\n\nPlease refer to the study contact for further eligibility details.","ALL","18 Years","59 Years",{"count":76,"type":77},130,"ESTIMATED","INTERVENTIONAL",[80],"PHASE3","The purpose of the study is to learn about the immune response after a RSVpreF vaccination. This study is being conducted in Japan. RSV is a common virus that can cause infections of the lungs and airways.\n\nThe study is seeking participants who are:\n\n* 18 to 59 years of age\n* adults with health condition(s) that can put them at an increased risk of severe RSV disease\n\nIt will also learn about the safety of RSVpreF vaccination. The study lasts about 2 months. Adults need to visit the research site at least 2 times. The participant will receive a phone call 2 months after vaccination for health checks.",[83],"Respiratory Syncytial Virus (RSV)",[85,86],"RESPIRATORY SYNCYTIAL VIRUS (RSV)","ADULTS AT HIGH RISK","2026-05-28",{"date":89,"type":90},"2026-06-02","ACTUAL",{"date":92,"type":90},"2026-05-11",{"date":94,"type":77},"2026-08-31",{"name":5,"class":6},5]